APTOCROM Inc. Stock

A109960

KR7109960005

Pharmaceuticals

End-of-day quote Korea S.E. 30/09/2026			5-day change	1st Jan Change
1,887.00 ^KRW	+1.23%		+0.16%	-62.26%

09-23	Aprogen Medicines Inc. announced that it has received KRW 20 billion in funding from N2Tech Co.,Ltd, APTOCROM Inc., Aprogen Pharma Inc.	CI
09-03	Aprogen Medicines Inc. announced that it expects to receive KRW 20 billion in funding from N2Tech Co.,Ltd, APTOCROM Inc., Aprogen Pharma Inc.	CI

Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
30/09/26	₩1,887.00	+1.23%	670
29/09/26	₩1,864.00	+0.43%	660
28/09/26	₩1,856.00	+0.11%	2,718
23/09/26	₩1,854.00	-1.59%	1,130
22/09/26	₩1,884.00	+1.56%	859

End-of-day quote Korea S.E.

More quotes

Stock Market
Stocks
A109960 Stock

As early as today, start finding the best investment opportunities!

Market Cap	28.55B 21.05M 18.57M 17.57M 15.94M 29.88M 2.02B 30.18M 211M 81.25M 1.03B 79.03M 77.31M 3.32B	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	11.35B 8.37M 7.39M 6.99M 6.34M 11.89M 803M 12M 83.86M 32.32M 410M 31.44M 30.75M 1.32B	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

09-23	Aprogen Medicines Inc. announced that it has received KRW 20 billion in funding from N2Tech Co.,Ltd, APTOCROM Inc., Aprogen Pharma Inc.	CI
09-03	Aprogen Medicines Inc. announced that it expects to receive KRW 20 billion in funding from N2Tech Co.,Ltd, APTOCROM Inc., Aprogen Pharma Inc.	CI
08-13	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-01	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-26	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
05-07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
04-28	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
04-28	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
03-20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-16	APTOCROM Inc. announces Annual dividend	CI
11-13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

1 day	+1.23%
1 week	+0.16%
Current month	+1.45%
1 month	+0.64%
3 months	+7.77%
6 months	-44.17%
Current year	-62.26%

1 week	1,839	1,910
1 month	1,717	2,005
Current year	1,430	5,400
1 year	1,430	6,660
3 years	1,430	27,680
5 years	1,430	80,600
10 years	1,430	426,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	23/03/2022
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-
Jong-Su Kang SAM	Sales & Marketing	62	-

APTOCROM Inc. Stock

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news: APTOCROM Inc.

Quotes and Performance

Price Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Director	Title	Age	Since
Soon-Kyu Park BRD	Director/Board Member	59	-
Jung-Chool Kim BRD	Director/Board Member	70	23/03/2022
Jae-Seob Kim BRD	Director/Board Member	63	10/01/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	+1.23%	+0.16%	-71.50%	-92.38%	20.79M
ELI LILLY AND COMPANY	-0.05%	+2.93%	+55.28%	+120.10%	1,056B
JOHNSON & JOHNSON	-0.03%	-0.36%	+44.64%	+72.86%	645B
ABBVIE INC.	+0.13%	-0.49%	+13.93%	+77.93%	465B
MERCK & CO., INC.	-1.60%	-0.77%	+75.07%	+43.29%	368B
ROCHE HOLDING AG	-0.36%	-4.05%	+34.09%	+40.50%	335B
NOVARTIS AG	-0.20%	+2.62%	+20.54%	+29.25%	275B
ASTRAZENECA PLC	-0.83%	-0.87%	+10.19%	+12.53%	255B
AMGEN INC.	-0.09%	+4.35%	+50.17%	+59.13%	229B
GILEAD SCIENCES, INC.	-0.70%	-0.56%	+35.60%	+103.13%	188B
Average	-0.19%	+0.13%	+26.80%	+46.63%	381.58B
Weighted average by Cap.	-0.25%	+0.30%	+41.70%	+74.35%

	2024	2025
Net sales	16.4B 12.09M 10.67M 10.1M 9.16M 17.17M 1.16B 17.34M 121M 46.68M 592M 45.4M 44.42M 1.91B	9.81B 7.23M 6.38M 6.04M 5.48M 10.27M 694M 10.37M 72.43M 27.92M 354M 27.15M 26.56M 1.14B
Net income	-28.09B -20.71M -18.28M -17.3M -15.69M -29.41M -1.99B -29.7M -207M -79.96M -1.01B -77.78M -76.09M -3.27B	-5.56B -4.1M -3.62M -3.42M -3.1M -5.82M -393M -5.88M -41.06M -15.82M -201M -15.39M -15.06M -646M
Net Debt	-25.07B -18.48M -16.31M -15.43M -14M -26.24M -1.77B -26.5M -185M -71.35M -906M -69.4M -67.89M -2.91B	-17.19B -12.68M -11.19M -10.58M -9.6M -18M -1.22B -18.17M -127M -48.94M -621M -47.6M -46.56M -2B